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Summary. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe reaction to drugs. 
Incidence of DRESS in children is not well known and the mortality rate seems to be lower than 10%. Anti-
convulsants are the main drugs involved both in adults and in children. The treatment of choice is intravenous 
immunoglobulins and corticosteroids used in synergy. Today there are not controlled clinical trials regarding 
DRESS treatment in children. Anyway, the prompt withdrawn of the offending drug is of paramount impor-
tance for a better prognosis. DRESS sequels may occur, consequently, follow-up visits are required at least 
until the first year after the reaction. (www.actabiomedica.it)
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Epidemiology
Drug reaction with eosinophilia and systemic 
symptoms (DRESS) is a serious and potentially fa-
tal adverse reaction to therapeutic medications. Over 
the last 80 years, the nomenclature of this disease has 
been changing from drug-induced pseudolymphoma, 
anticonvulsant hypersensitivity syndrome, drug in-
duced hypersensitivity syndrome (DIHS), drug in-
duced de layed multiorgan hypersensitivity syndrome 
to DRESS. DRESS is classified among severe cutane-
ous adverse reactions (SCARs) and in 1966 Bocquet 
et al. (1) identified it as a distinct clinical syndrome. 
Moreover, the meaning of “R” in DRESS acronym has 
been changed from Rash to Reaction due to the het-
erogeneity of skin eruptions (2). Initially, DRESS was 
thought to affect only adults, later it was diagnosed 
also in children (3).
The incidence of DRESS due to antiepileptics is 
in the range of 1:1000 to 1:10.000 in general popu-
lation (4) and of 0.4:1000 (5) in hospital settings. In 
younger children the incidence of DRESS seems to 
be lower than in adults, although the real incidence is 
not known (6,7). Anyway, DRESS is more frequent 
than other severe immediate drug-induced reactions 
such as anaphylaxis (8), or exercise-induced anaphy-
laxis (9) but less common than food-induced anaphy-
laxis (10,11). The overall mortality rate is of 10% with 
a lower percentage in children than in adults (12-13). 
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Pathogenesis
DRESS is the result of a complex interplay of ge-
netic factors [ethnic predisposition in people with cer-
tain human leucocyte antigen (HLA) alleles], immu-
nological response, abnormalities in metabolic path-
ways (such as a deficiency or abnormality in epoxide 
hydroxylase, an enzyme that detoxifies the metabolites 
of aromatic amine anticonvulsants) and associated re-
activations of herpes virus family members (HHV-6 
and HHV-7, EBV and CMV) (14). In this context, 
African Americans are most likely to develop DRESS 
syndrome after initiation of aromatic anticonvulsants 
drugs whereas the Han Chinese are most likely to de-
velop DRESS after allopurinol intake (15).
In fact, it has been found that DRESS syndrome 
is associated with certain human leukocyte antigens 
(HLAs), such as, HLA A*31:01 (aromatic anticon-
vulsant-induced DRESS); HLA A* 24:02 (lamotrig-
ine-induced DRESS); HLA B*51:01, HLA B*15:13 
and CYP2C9*3 (phenytoin-induced DRESS); 
HLA-B*57:01 and DRB1*01:01 and HLAB*35:05 
(abacavir-induced DRESS) and HLA-B*58:01 (al-
lopurinol-induced DRESS); HLA C*04:01 (nevirap-
ine-induced DRESS) (16-19). 
Apart from HLA, cytochrome P4502C9 marker 
has been reported to be involved in phenytoin induced 
SCARs (20-21). 
Moreover, being a slow acetylator of drugs is 
thought to be a risk factor for DRESS syndrome (22). 
Drugs may act as foreign antigens, binding to 
HLA/peptide/TCR complex and inducing hypersen-
sitivity reactions. DRESS is a delayed type reaction ac-
cording to Gell and Coombs classification (23).
There are four hypotheses regarding drug presenta-
tion mechanisms that have been suggested to explain 
how small drug molecules might interplay with HLA 
and TCR in drug hypersensitivity: (1) the hapten theo-
ry, (2) the pharmacological interaction with immune re-
ceptors (p-i) concept (i.e. carbamazepine directly inter-
acts with HAL B*15:02) (3) the altered peptide reper-
toire model (i.e. abacavir binds to the F-pocket of HLA 
B*57:01), and (4) the altered TCR repertoire model (i.e. 
sulfamethoxazole directly interacts with TCR).
In delayed type reactions such as DRESS syn-
drome, drug antigens may activate specific T lympho-
cytes or natural killer cells with production of various 
cytokines/chemokines (i.e. TNF-α, IFN-γ, IL-2, IL-
4, IL-5, TARC/CCL17, IL-6, IL-15, and IL-13) (16).
Furthermore, viruses have also been proposed to 
be involved in HLA/drug/TCR interactions and play 
an important role in drug hypersensitivity reactions, 
representing a source of exogenous peptides for drug 
presentation (24). 
So far, the role of viruses in the pathogenesis of 
DRESS is unclear: a) Viral reactivation may be pro-
voked by a cytokine storm secondary to an immune 
response against the drug (25); b) DRESS is a conse-
quence of a strong immune response against an early 
viral reactivation (26). CD4+ and CD8+ drug-specific 
T cells proliferate after encountering the drug, but 
also anti-viral specific T cell can be cross-activated by 
drugs. In conclusion, the most common hypothesis 
is that the immunologic response to drugs induces a 
boost viral reactivation, consequently T lymphocytes 
and monocytes/macrophages release viruses that rep-
resents as an early marker of stimulation of these cells, 
rather than the triggering event in the pathogenesis of 
DRESS (27). In particular, toxic drug metabolites ac-
cumulation provoke an immunosuppression of B cells 
with hypogammaglobulinemia and subsequent viral 
re-activation (28). For example, in Asia and Europe 
the detection of HHV-6 copies in DRESS cases has 
been commonly reported with a frequency of 70-80%, 
making this data as an available diagnostic test (29, 
30). 
Clinical manifestations 
The time onset of DRESS symptoms ranges from 
2-6 weeks after initiation of treatment (2), anyway la-
tency periods up to 105 days have been described (31).
Retrospective studies have found that the aver-
age age of occurrence of DRESS syndrome is 9 years 
of age in children (7,13). The most common clinical 
feature is fever, which is usually high grade ranging 
from 38-40°C. The second most common feature is 
macular erythema. This kind of rash later evolves in 
more violaceous and papular lesions with or without 
pruritus (Figure 1), and over time, the eruption be-
comes potentially exfoliative. Consequently, although 
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a maculopapular rash is the most common initial cuta-
neous manifestation other eruptions may be described, 
including targetoid, urticarial, pustular, blistering, 
lichenoid, exfoliative, and eczematous lesions. The 
skin eruption typically begins on the face associated 
to facial oedema and then involves the upper trunk 
progressively spreading at lower extremities. The skin 
can be involved from less than 50% of body surface to 
diffuse erythroderma, making consistent the cutane-
ous distribution of the eruption. Moreover, mucosal 
involvement has been frequently (>50%) described (i.e. 
conjunctivitis, oral mucositis and/or genital lesions) in 
DRESS (7).
The eruption can persist for months after the of-
fending drug has been discontinued. Lymphadenopa-
thy is the third most common presentation, which is 
seen in 70-75% of patients (32). 
Haematological abnormalities, such as leucocy-
tosis, eosinophilia, atypical lymphocytosis, throm-
bocytopenia and agranulocytosis commonly occur in 
DRESS.
Eosinophilia is typically reported in DRESS 
studies from both Asia and Europe with percentages 
ranging from 48 to 95% of patients (2, 7, 33). 
Among visceral organ, liver (i.e. hepatitis) is in-
volved in 50-80% of patients, followed by kidney (i.e. 
nephritis with haematuria or acute renal failure) in 
11-28% of patients. Unfortunately, in some patients, 
hepatic injury can progress to widespread hepatic ne-
crosis and fulminant liver failure (29, 34, 35) and it 
represents the leading cause of mortality in these pa-
tients (36).
Lungs (i.e. pneumonitis) are involved in 2.6-5% 
patients, but also muscle (myositis), gastrointestinal 
(i.e. colitis) heart (i.e. myocarditis), pancreas (i.e. pan-
creatitis), brain (i.e. encephalitis), thyroid (i.e. thyroid-
itis) and conjunctiva (i.e. conjunctivitis) involvements 
have been described (31 37). In table 1 are reported 
the clinical features of DRESS syndrome (29, 35, 36, 
38-44). Clinical manifestations were similar between 
children and adults, with the exception of pulmonary 
involvement (excluding asthma), which was more 
Figure 1. Acute Rash in DRESS syndrome
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frequent in adults, and gastrointestinal involvement, 
which was more frequent in children (42).
Drugs Involved
More than 40 medications have been described as 
triggers of DRESS and among various drugs, aromatic 
antiepileptics are reported to be the most common cause 
followed by antibiotics. Moreover, aromatic anticon-
vulsants show cross-reactivity in 40-80% of cases while 
non aromatic anticonvulsants are well tolerated as alter-
native choice in case of reactions to aromatics.  Anyway, 
data about DRESS in children are scarce and mostly 
come from case reports. In the study of Misirlioglu et al 
(45), antibiotics were the most common (50%) medica-
tion in the aetiology; 87.5% of the suspected antibiotics 
were beta-lactams, and 12.5% were macrolides. Antie-
pileptics were second (37.5%, n. 6) most common class 
of drugs in the aetiology. In Table 2 we reported the 
drugs most frequently involved in DRESS syndrome 
in children in the last ten years. Studies where children 
were included but not clearly specified in terms of age 
and culprit drugs, were excluded. 
Table 1. Most common clinical features of DRESS syndrome and percentages of organ involvement
Fever (>38°C) 86.5% (38)
Acute Rash 85% (38)
Facial Swelling with periorbital involvement 27% (38)
Lymphadenopathy 70% (38)
Eosinophilia 60-80% (29, 30, 38)
Liver:
Hepatomegaly and/or increase liver enzymes (AST/ALT) and/or hyperbilirubinemia; elevated 51-84% (35, 36, 40-41)
Alkaline phosphatase (30) 
Kidney: 11-57% (35, 40-41)
Elevation in creatinine
Decrease in glomerular filtration rate (GFR)
Proteinuria
Haematuria
*Allopurinol is most commonly implicated with renal involvement (36) 




Acute respiratory distress Syndrome (ARDS)
*Minocycline, Allopurinol, Abacavir are most commonly implicated with lung involvement (26, 37) 
Non specific Gastrointestinal Symptoms: 8% (35, 42) 
Colitis
Diarrhoea with or without electrolyte abnormalities 
Heart: Late onset Myocarditis (Troponin and CKMB elevated) 4-27% (43,44)
Tachycardia, arrhythmias, chest pain, non specific ECG changes, gross ST segment, elevation 
or depression, decrease in LV ejection fraction
* Ampicillin is most commonly implicated with heart involvement 
F. Mori, C. Caffarelli, S. Cammi, et al.70
Table 2. Most frequently reported drugs causing DRESS syndrome in children
Single case or less than 10 children (mean age 7,6 years) (46-114) • carbamazepine 14/103 (13.6%)
 • phenytoin 12/103 (11.7%)
 • phenobarbital 9/103 (8.8%)
 • valproic acid 6/103 (5.9%)
 • vancomycin 5/103 (5%)
 • lamotrigine 4/103 (4%)
 • cefotaxime 4/103 (4%)
 • trimethoprim-sulfamethoxazole 4/103 (4%)
 • ceftriaxone 3/103 (3%)
 • levetiracetam 3/103 (3%)
 • dapsone 3/103 (3%)
 • clindamycin 2/103 (2%)
 • piperacillin-tazobactam 2/103 (2%)
 • azithromycin 2/103 (2%)
 • oxacarbamazepine 2/103 (2%)
 • minocycline 2/103 (2%)
 • sulfadiazine 2/103 (2%)
 • oxacilline 2/103 (2%)
 • penicillin 2/103 (2%)
 • cefixime 1/103 (0.9%)
 • naproxen 1/103 (0.9%)
 • canakinumab 1/103 (0.9%)
 • amoxi-clav 1/103 (0.9%)
 • anakinra 1/103 (0.9%)
 • tobramycin 1/103 (0.9%)
 • ibuprofen 1/103 (0.9%)
 • acetylsalicylic acid 1/103 (0.9%)
 • griseofulvine 1/103 (0.9%)
 • sulthiame 1/103 (0.9%)
 • infliximab 1/103 (0.9%)
 • fluoxetina 1/103 (0.9%)
 • cefepime 1/103 (0.9%)
 • allopurinol 1/103 (0.9%)
 • perampanel 1/103 (0.9%)
 • cefditoren-pivoxil 1/103 (0.9%)
 • paracetamol 1/103 (0.9%)
 • Ethambutol+rifampin+pyranzinamide 1/103 (0.9%)
 • pyrimethamine 1/103 (0.9%)
 • rufinamide 1/103 (0.9%)
32 children (mean age 8,9 y) (13) • 13 carbamazepine
 • 12 phenytoin
 • 5 phenobarbital
 • 5 lamotrigine
 • 1 primidone
 • 1 oxcarbamazepine
33 children (mean age 5,8 y) (115) • 18 phenobarbital
 • 15 phenytoin
(continued)
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Diagnosis
Due to the variability of its presentation, DRESS 
is known as “the great mimicker” making difficult 
the diagnosis (118). In particular, DRESS symptoms 
resemble those of cutaneous and systemic infectious 
diseases and can appear up to 3 months after the ini-
tial culprit drug exposure. The allergy work-up should 
start with a detailed record of clinical history by focus-
ing on the chronology of drug assumptions and physi-
cal examination. Laboratory testing is fundamental, it 
should include liver, and kidney functions, search for 
viral infections, complete blood count and coagulation 
testing.
There are no clear and specific histopathological 
patterns in skin biopsy that are characteristic of DRESS 
Syndrome. Maculopapular exanthema (MPE) may be 
the initial presentation of SCARs including DRESS 
(119-120). When comparing DRESS with MPE, skin 
biopsies showed differences in terms of inflammatory 
infiltrate, atypical lymphocytes, keratinocyte damage, 
dermal involvement and leukocytoclastic vasculitis, 
these characteristics being more frequently observed in 
DRESS cases than in MPE cases (86, 121). Few necrotic 
keratinocytes were associated with non-severe DRESS 
cases, otherwise high amount of necrotic keratinocytes 
with confluent necrotic areas were associated with se-
vere DRESS, respectively. Anyway, the role of skin or 
lymph node biopsies remains controversial (119).
Eosinophilia is a diagnostic criterion for DRESS. 
In physiologic conditions, eosinophils are not present 
in skin, liver, lungs or other internal organs otherwise 
in DRESS, eosinophils are typically increased in blood, 
in skin and in involved organs. Eosinophils infiltrate 
Table 2 (continued). Most frequently reported drugs causing DRESS syndrome in children
29 children (mean age 11 y) (116) • 10 trimethoprim-sulfamethoxazole
 • 3 phenytoin
 • 3 amoxicillin
 • 2 cefalosporins
 • 2 lamotrigine
 • 2 minocyclin
 • 2 macrolids
 • 2 oxcarbamazepine
 • 1 carbamazepine
 • 1 clindamycin
 • 1 zonisamide
11 children (mean age 6,6 y) (117) • 4 lamotrigine
 • 1 cefotaxime
 • 2 carbamazepine
 • 1 phenytoin + phenobarbital
 • 3 amoxi-clav
16 children (mean age 8,2 y) (45) • 3 amoxi-clav
 • 1 ampicillin-sulbactam
 • 2 cefdinir
 • 1 cefotaxime
 • 1 clarythromycin
 • 3 carbamazepine
 • 1 lamotrigine
 • 1 phenytoin
 • 1 phenobarbital
 • 1 sulfasalazine
 • 1 oxymetazoline nasal spray
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organs in response to cytokines and chemokines in-
cluding eotaxin-1, TARC, IL-5 and granule release 
representing key factors of tissue damage (122). 
The discovery of biomarkers of drug hypersen-
sitivity could be useful for the diagnosis of DRESS 
syndrome.  In DRESS cases, serum TARC levels have 
been reported to be significantly higher than those in 
patients with Steven-Johnson Syndrome (SJS)/Toxic 
epidermal necrolysis (TEN) and MPE during the 
acute phase and to be correlated with skin eruptions 
(122). For this reason, TARC could be considered a 
potential biomarker for the early phase and disease ac-
tivity of DRESS syndrome. 
Re-challenging with the offending drug has been 
considered the gold standard to diagnose drug erup-
tions, but in suspected DRESS cases, it should not be 
used because of the life-threatening nature of this syn-
drome (2, 123). Patch tests can be useful to prove a 
drug-specific immune response in DRESS syndrome 
(124). On the contrary, patch tests to different al-
lergens such as foods have a low diagnostic accuracy 
(125). In vivo patch tests represent a low-risk method 
for reproducing delayed hypersensitivity by re-expos-
ing patients to low amount of suspected offending 
drugs.  Anyway, the sensitivity and specificity of patch 
tests are different according to the drug tested.
The lymphocyte transformation/activation test 
(LTT/LAT) measures the proliferation of T cells to a 
drug (126, 127). Unfortunately, it is not standardized 
for many medications and it is difficult to perform. 
Furthermore, it usually yields a negative result early 
in the course of the syndrome, and lacks sensitivity. A 
positive LTT/LAT is useful to confirm the diagnosis 
due to very low false positive results (only 2%), how-
ever a negative test cannot exclude the diagnosis (128). 
All these factors prevent widespread use of this test. 
For the diagnosis of DRESS syndrome different 
criteria can be used such as Bocquet’s criteria (1), The 
European Registry of Severe Cutaneous Adverse Re-
actions to Drugs and Collection of Biological Sam-
ples (RegiSCAR) criteria (7) and the Japanese group 
of Severe Cutaneous Adverse Reactions to Drugs 
(SCAR-J) criteria (Table 3). The RegiSCAR is most 
often used to diagnose DRESS (129), it is based on 
seven independent parameters and three of them are 
required for the diagnosis of DRESS. According to 
RegiSCAR, the diagnosis of DRESS can be definite 
(score >5), probable (score 4-5), possible (score 2-3) 
and no (score <2) DRESS syndrome. 
Differential Diagnosis
DRESS should be differentiated from viral ex-
anthemas especially EBV infectious mononucleosis, 
staphylococcal and streptococcal shock syndrome, 
meningococcemia, non infectious drug eruptions (e.g. 
SJS/TEN), autoimmune diseases (e.g. hypereosino-
philic syndrome, Kawasaki disease, Stills diseases), 
urticaria vasculitis (130), neoplastic diseases (e.g. leu-
kemia cutis, pseudolymphoma, mycosis fungoides), se-
rum sickness like reaction, and atopic eritrodermia. In 
the last, for example, nephritis and hepatitis are lack-
ing, being caused by bacterial infections (131).
Depending on organs involved, the differential 
diagnosis also includes viral hepatitis (liver), parasitic 
infection (gastrointestinal tract) and bacterial, viral 
and fungal pathogens (lung) (36).
Treatment
So far, there have been no prospective clinical tri-
als on treatment of DRESS syndrome. Current rec-
ommendations are based on case reports and expert 
opinion (132). The first and most important step in 
treatment of DRESS is withdrawal of the causative 
drug, because a better prognosis is associated with an 
earlier discontinuation of the drug. 
In mild forms, treatment is mainly supportive 
and symptomatic, consisting of topical steroids, sys-
temic anti-H1 antihistamines and emollients for rash 
and itching. In patients with exfoliative dermatitis a 
prompt and appropriate fluid, electrolyte and nutri-
tional support is of primary importance. In moderate 
cases without visceral involvement, corticosteroids are 
usually adequate (133). 
In case of organ involvement, such as liver 
(transaminases >5 times upper limit of normal), kidney, 
lungs or heart, the expert opinion of French Society of 
Dermatology recommended to administer corticoster-
oid (prednisone, 1 mg/kg/day per os). Several aspects 
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(i.e. optimal dose, route of administration, duration 
of treatment, and rapidity of dose tapering) of ster-
oid treatment have not been compared in controlled 
trials (119). Tapering should take three to six months 
of time because rapid taper can be associated with 
relapse of DRESS (119, 134, 135). Systemic steroid 
therapy is advised to treat cases of moder ate to severe 
disease taking into account the dramatic improvement 
in symptoms and frequent relapses of DRESS associ-
ated with quick prednisone taper. For all these reasons, 
intravenous pulses of methylprednisolone (1 g/d) are 
recommended especially in patients worsening despite 
adequate doses of oral corticosteroids (52). 
Proposed mechanism by which corticosteroids 
benefit the patient is inhibition of IL-5, which attracts 
eosinophils, which are responsible for visceral organ 
damage by accumulation in DRESS syndrome (35). 
For the same reason, some authors proposed the use of 
mepolizumab (anti IL-5) in the treatment of DRESS 
(136). 
Today, cyclosporine may be considered a second-
line therapy for patients with severe organ involve-
ment who do not respond to systemic corticosteroids 
and for patients in whom corticosteroids are contrain-
dicated (137). Intravenous immunoglobulins (IVIG) 
have been reported to be useful in a few patients with 
DRESS and detrimental in others (138). Periodical 
controls (both clinical and laboratory parameters) are 
necessary to check progression of the skin eruption 
and/or development of clinical fatal life-threatening 
signs, which include hemophagocytosis with bone 
marrow failure, encephalitis, severe hepatitis, renal 











Bocquet et al. (1)
≥3 criteria
- acute drug eruption
- eosinophilia >1.5×109/L or 
atypical lymphocytosis
- lymphadenopathy ≥2 cm in 
diameter
- hepatitis with liver 






≥3 criteria of the following asterisk 
marks
- hospitalization




one of the following hematologic
abnormalities
- eosinophilia over laboratory 
limits
- lymphocyte count over and 
under normal limits
- thrombocytopenia under 
laboratory limits
- lymphadenopathy involving ≥2 
sites*
- at least 1 internal organ 
involvement*
J-SCAR (129)
all 7 criteria = typical
without 2 asterisk marks = atypical
- symptoms persisting at least 2 
weeks after drug discontinuation
- fever ≥38°C
- macular rash developing 3 weeks 
after starting offending drug
one of the following hematologic
abnormalities
- leucocytosis (>11×109 /L)
- atypical lymphocytes (>5%)
- eosinophilia (>1.5×109 /L)
- lymphadenopathy*
- liver abnormalities (ALT >100 
U/L)
- HHV-6 reactivation*
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failure, and respiratory failure requiring treatment 
with steroids generally administered at a dose of 2 g/
kg over 5 days with IVIG. The largest series of paedi-
atric patients have been described by Marcu N et al. 
(62) who reported 7 patients with severe DRESS in 
whom treatment with IVIG (1-2 gr/kg) in addition to 
systemic corticosteroids was successful. One possible 
explanation is that IVIG preparations contain anti-
viral neutralizing antibodies that help clear the viral 
infection/reactivation found to be fundamental in the 
pathophysiology of DRESS. Anyway, IVIG should 
not be administered in the absence of steroids.
Due to the fact that there is a major viral reac-
tivation along with presence of life-threatening signs, 
it has been proposed to administer anti-viral medica-
tions (e.g. ganciclovir) in combination with steroids 
with or without IVIG but the efficacy is unclear (139).
In severe and corticosteroid-resistant cases, more 
potent immunosuppressant medications includ ing 
cyclosporine, azathioprine, rituximab, infliximab and 
mycophenolate have been used, sometimes alongside 
adjunctive treatment with IVIG and plasmapheresis 
(42, 66, 140, 141). N-acetyl cysteine (NAC), which 
acts as detoxifying drug, can also be used in DRESS.
Finally, the treatment of DRESS syndrome 
should be started immediately after diagnosis, even 
if the result of viral markers are still ongoing. Fur-
ther studies with appropriate designs (i.e. randomized 
controlled trials) are needed to establish a standard of 
care in DRESS. Such studies should also assess the 
potential application of anti-viral drugs or probiotics 
for treating infections (142, 143, 144).
Prognosis
After withdrawal of the causative drug, most of 
the patients need some weeks to completely recover. 
The prevalence of sequelae is unknown. Long-term se-
quelae may be renal failure, chronic anaemia, autoim-
mune diseases (autoimmune thyroid disease, diabetes 
melli tus type I, systemic lupus erythematous (SLE), 
systemic scle rosis, adrenal insufficiency and autoim-
mune haemolytic anaemia). For example, thyroiditis 
has been reported in the 12.5% of children with a pre-
vious DRESS (7). 
Moreover, recurrence of DRESS with unrelated 
drugs can be observed in 25% of cases, whereas very 
little or no flares are reported in patients after SJS/
TEN (145, 146). 
Those manifestations can occur months to years 
following the initial episode and awareness of associa-
tion with a drug administration is crucial to promptly 
recognise and treat a possible DRESS. Fol low-up vis-
its at 2, 3, 4, 5, 6, 12 months and then once a year are 
recommended (146, 148).
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